Eric Deneuville

ORCID: 0000-0002-4369-0000
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cystic Fibrosis Research Advances
  • Tracheal and airway disorders
  • Neonatal Respiratory Health Research
  • Pneumonia and Respiratory Infections
  • Pediatric health and respiratory diseases
  • Respiratory viral infections research
  • Asthma and respiratory diseases
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Tuberculosis Research and Epidemiology
  • Antifungal resistance and susceptibility
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Nematode management and characterization studies
  • Antibiotics Pharmacokinetics and Efficacy
  • Fungal Infections and Studies
  • Dysphagia Assessment and Management
  • Child Nutrition and Feeding Issues
  • Infant Nutrition and Health
  • Medical Imaging and Pathology Studies
  • Genetic and Kidney Cyst Diseases
  • Breastfeeding Practices and Influences
  • Lung Cancer Diagnosis and Treatment
  • Antibiotic Resistance in Bacteria
  • Family and Disability Support Research
  • HIV/AIDS drug development and treatment
  • Pediatric Hepatobiliary Diseases and Treatments

Centre Hospitalier Universitaire de Rennes
2007-2025

CIC Rennes
2015

Hôpital Nord
2006-2009

Université de Reims Champagne-Ardenne
1997

Inserm
1997

Centre Hospitalier Universitaire de Reims
1997

Pierre‐Régis Burgel Isabelle Sermet‐Gaudelus Emmanuelle Girodon I. Durieu Véronique Houdouin and 95 more Camille Audousset Julie Macey Dominique Grenet Michele Porzio M. Murris‐Espin Philippe Reix Mélisande Baravalle Chantal Belleguic Laurent Mély Juliette Verhille Laurence Weiss Martine Reynaud‐Gaubert M. Mittaine Rébecca Hamidfar Sophie Ramel Laure Cosson Benoît Douvry Isabelle Danner‐Boucher P. Foucaud Charlotte Roy Espérie Burnet Caroline Raynal M.‐P. Audrézet Jennifer Da Silva C. Martín Reem Kanaan Nicolas Carlier Isabelle Honoré Frédérique Chedevergne Elise Dréano Aurélie Hatton Alexandre Hinzpeter Iwona Pranke Laurence Le Clainche-Viala Sophie Mayer Harriet Corvol Guillaume Thouvenin Sandra de Miranda Natascha Remus Benoît Douvry L. Duthoit T. Pérez Olivier Le Rouzic Nathalie Wizla Claire Bon S. Bui Nora Poey Nathalie Stremler Bérengère Coltey Nadine Dufeu Jean Lebihan Asma Gabsi Delphine Pouradier Claire Andréjak Cinthia Rames Magali Dupuy-Grasset Jeanne Languepin Christophe Marguet S. Pramil Baptiste Arnouat Annlyse Fanton M. Abély Bruno Ravoninjatovo Aurore Blondé Anne Guillaumot Sébastien Kieffer Aurélie Tatopoulos R. Nové-Josserand Camille Ohlmann Thomas Perrin Quitterie Reynaud C. Llerena S. Quétant Sophie Valois Marie‐Laure Dalphin Bénédicte Richaud-Thiriez Eric Deneuville R. Chiron Floriane Socchi Tiphaine Bihouée Julie Mankikian Thomas Flament Nathalie Coolen-Allou Elsa Gachelin Caroline Périsson Constance Vuillard Marion Dupuis Wael Alkoussa Sarah Marchal Sylvie Leroy Manuëla Scalbert Karine Campbell Muriel Laurans Guillaume Labbé Sylvie Montcouquiol

10.1016/s2213-2600(24)00208-x article EN The Lancet Respiratory Medicine 2024-08-13

ABSTRACT The present multicenter, randomized crossover study compared the safety and efficacy of continuous infusion with those short infusions ceftazidime in patients cystic fibrosis. Patients chronic Pseudomonas aeruginosa colonization received two successive courses intravenous tobramycin (200 mg/kg body weight/day) for pulmonary exacerbation administered as thrice-daily or a infusion. primary endpoint was variation forced expiratory volume 1 s (FEV ) during course antibiotic treatment....

10.1128/aac.00174-09 article EN Antimicrobial Agents and Chemotherapy 2009-06-16

The diagnosis of cystic fibrosis (CF) is based on a characteristic clinical picture in association with sweat chloride (Cl(-)) concentration greater than 60 mmol/L or the identification two CF-causing mutations. A challenging problem significant number children for whom no definitive possible because they present symptoms suggestive CF, level intermediate range between 30 and mmol/L, only one identified mutation.To investigate function transmembrane conductance regulator (CFTR) protein...

10.1164/rccm.201003-0382oc article EN American Journal of Respiratory and Critical Care Medicine 2010-06-11

Highly effective CFTR modulators, such as elexacaftor/tezacaftor/ivacaftor (ETI), herald a new era in therapeutic strategy of cystic fibrosis (CF). ETI impact on glucose tolerance remains controversial. All the participants underwent baseline oral test (OGTT) before initiation (M0) and 12 months (M12), at 24 if possible. The cohort was stratified two subgroups based OGTT: normal (NGT) abnormal (AGT) defined by impaired fasting or diabetes not requiring insulin treatment. We included 106...

10.1210/clinem/dgaf099 article EN publisher-specific-oa The Journal of Clinical Endocrinology & Metabolism 2025-02-20

Elexacaftor/tezacaftor/ivacaftor (ETI) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) therapy that improves pulmonary function and chronic rhinosinusitis (CRS) in cystic fibrosis (CF) adults with at least one copy of the F508del CFTR mutation. The purpose this study to evaluate impact ETI on CRS symptoms children adolescents CF. MODUL-CF observational multicenter prospective cohort enrolling CF 1 mutation France. Subjects answered standardized questionnaire nasal obstruction...

10.1002/alr.23557 article EN cc-by-nc-nd International Forum of Allergy & Rhinology 2025-03-06

Aspergillus fumigatus triazole resistance is an emerging concern for treating chronically infected/colonized patients. This study sought to evaluate the performance of PCR assays detect fungi together with azole in sputum samples from cystic fibrosis (CF) In total, 119 87 CF patients were prospectively processed detection by means mycological culture and four qPCR assays, 2 in-house methods two commercial multiplex real-time simultaneously detecting most relevant cyp51A gene mutations...

10.3389/fmicb.2018.00531 article EN cc-by Frontiers in Microbiology 2018-03-27

We investigated the physicochemical and transport properties of sputum samples collected in physiotherapy from a well-documented group 27 cystic fibrosis (CF) patients with identified CF genotypes. Sputum were characterized ex vivo for their water content, surface (surface tension contact angle), rheologic (viscosity elastic modulus), (mucociliary cough transport). These data analyzed relation to clinical status (FEV1, FVC, Shwachman score, Brasfield nutritional status), genotype, degree...

10.1164/ajrccm.156.1.9606123 article EN American Journal of Respiratory and Critical Care Medicine 1997-07-01

Viral infections such as influenza are thought to impact respiratory parameters and promote infection with Pseudomonas aeruginosa in patients cystic fibrosis (CF). However, the real morbidity of virus CF needs be further investigated because previous studies were only observational. included a case–control study (n = 44 cases n 371 controls) during 2009 pandemic A/H1N1 influenza. Cases polymerase reaction chain-confirmed infection. Controls did not report any symptoms same period. Sputum...

10.1186/s12879-016-1352-2 article EN cc-by BMC Infectious Diseases 2015-12-01

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections are closely monitored in people with cystic fibrosis (pwCF), especially severe cases. Previous studies used hospitalization rates as proxy for severity. Methods We evaluated data from disease 2019 (COVID-19) cases diagnosed French pwCF over the first pandemic year. Objective criteria were applied defining severity (eg, failure and/or death). Data compared to all using National Registry. Results As of...

10.1093/cid/ciac333 article EN Clinical Infectious Diseases 2022-04-26

Abstract Background Cystic fibrosis (CF) is caused by mutations in the gene encoding for CF transmembrane conductance regulator (CFTR) protein, which acts as a chloride channel after activation cyclic AMP (cAMP). Newborn screening programs usually consist of an immunoreactive trypsinogen (IRT) assay, followed when IRT elevated testing panel CF-causing mutations. Some children, however, may have persistent hypertrypsinogenemia, only one or no identified CFTR mutation, and sweat concentrations...

10.1186/1471-2431-6-25 article EN cc-by BMC Pediatrics 2006-10-03

Lung damage in cystic fibrosis (CF) is strongly associated with lower airway infections. Early treatment of Pseudomonas aeruginosa recommended. Pathogen detection requires sampling secretions, which remains a challenge nonexpectorating patients. Our hypothesis was that chest physiotherapy would improve the quality secretion samples and increase rates pathogens detected This prospective multicentre study compared three successive methods for secretions applied through same session: 1) an...

10.1183/23120541.00513-2020 article EN cc-by-nc ERJ Open Research 2021-01-01

In the management of cystic fibrosis, treatments against Staphylococcus aureus and Haemophilus influenzae such as amoxicillin or cotrimoxazole have to be prescribed antibiotherapy's efficacy may linked concentration that reaches infected site. As fibrosis patients present disturbed pharmacokinetics parameters, drug monitoring would relevant assess lung distribution antibiotics optimize dosing regimens. this context, aim study was develop validate HPLC-based methods for determination both in...

10.1002/bmc.5208 article EN Biomedical Chromatography 2021-07-02

<b>Introduction:</b> Interstitial lung disease (ILD) in children (chILD) is rare and often severe. This study aims at analyzing the epidemiology of chILD France from 2000 to 2022. <b>Methods:</b> was retrospective multicentric. A questionnaire sent all RespiRare centers collect clinical, radiological, biological, histological genetic data patients. <b>Results:</b> 617 patients (0-18 years) were included 42 centers. 84 excluded. The median age diagnosis 0.3 years with 17% familial forms. main...

10.1183/13993003.congress-2023.pa420 article EN 2023-09-09
Coming Soon ...